Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Zeng, Zhi, Lu, Qiliang, Liu, Yang, Zhao, Junjun, Zhang, Qian, Hu, Linjun, Shi, Zhan, Tu, Yifeng, Xiao, Zunqiang, Xu, Qiuran, Huang, Dongsheng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8292964/
https://ncbi.nlm.nih.gov/pubmed/34307125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641522
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados